1 / 6

The PREVEND IT

The PREVEND IT. Source:

yamal
Télécharger la présentation

The PREVEND IT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The PREVEND IT Source: Brouwers FP, Asselbergs FW, Hillege HL, et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J. 2011;161(6):1171–1178.

  2. Background: This study understands the effect of treatment that is targeted at lowering urinary albumin excretion (UAE). Extended follow-up data of over 10 years has also been accumulated, which helped to investigate the long-term effects of fosinopril and pravastatin on cardiovascular (CV) outcomes.

  3. Aim: • (i) To investigate whether treatment targeted at lowering UAE would reduce adverse CV events (the PREVEND IT). • (ii) To investigate effects of fosinopril 20 mg and pravastatin 40 mg on CV outcomes in subjects with UAE >15 mg per 24 h (follow-up data of approximately 10 years).

  4. Methods: • Number of patients: 864 participants and 839 survivors after 4 years. • Primary endpoint of every survivor was determined by the combined incidence of CV mortality and hospitalization for CV morbidity. • Mean total extended follow-up in the PREVEND IT was 9.5 years (range: 9.4–10.7 years).

  5. Results: • No reduction in the primary endpoint compared to placebo was observed in fosinopril group after 4 years of treatment (hazard ratio [HR]: 0.87, 95% CI: 0.61–1.24 [p=0.42]). • Total event rate of 29.5% seen in subjects with a baseline UAE in the upper quintile (>50 mg/24 h) after 9.5 years. They were also at high risk for developing CV diseases (HR: 2.03, 95% CI: 1.38–2.97 [p≤0.01]). • Risk reduction of 45% observed in fosinopril treatment group compared to placebo (95% CI: 6–75% [p=0.04]). • No overall risk reduction in primary endpoint observed in subjects who were assigned to pravastatin (p=0.99).

  6. Conclusion: There exists a positive correlation between elevated UAE and CV mortality and morbidity; the CV risk doubles if the UAE exceeds >50 mg/day.

More Related